Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 4/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31632352 | 0.83 | ALDH1A1 (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL12055946 | 0.81 | TSHR (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9928962 | 0.80 | TSHR (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL14753933 | 0.77 | MEN1 (0.40) | ALDH1A1MAPTKMT2ADHODHSMN1; SMN2 | |
| SCHEMBL18817221 | 0.77 | HPRT1 (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL18816938 | 0.77 | POLB (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL15131962 | 0.77 | KMT2A (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4175674 | 0.77 | KMT2A (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL17744500 | 0.77 | GRIN2D (0.45) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL18817044 | 0.77 | HPGD (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-11725012-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | BEIGENE, LTD. (KY) | 2023-08-15 | — | — | US | disclosed |
| US-11725012-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | BEIGENE, LTD. (KY) | 2023-08-15 | — | — | US | disclosed |
| US-11725012-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | BEIGENE, LTD. (KY) | 2023-08-15 | — | — | US | disclosed |
| US-20230009843-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2023-01-12 | — | — | US | disclosed |
| EP-4086259-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2022-11-09 | — | — | EP | disclosed |
| CN-114805366-A | Imidazo [1,5-A ] pyrazine derivatives as PI3K delta inhibitors | 百济神州有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-110267959-B | Imidazo [1,5-A ] pyrazine derivatives as PI3K delta inhibitors | 百济神州有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220098202-A1 | IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-03-31 | — | — | US | disclosed |
| US-20220098202-A1 | IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-03-31 | — | — | US | disclosed |
| WO-2017079519-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2017-05-11 | — | — | WO | disclosed |
| US-9527848-B2 | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150284390-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2015-10-08 | — | — | US | disclosed |
| US-9096600-B2 | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-08-04 | — | — | US | disclosed |
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| EP-2655374-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | Incyte Corporation (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012087881-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2012-06-21 | — | — | US | disclosed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | disclosed |
| WO-2011075630-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PI4KB | GRIN2D 3104/4885GRIN3B 730/4885GRIN1 783/4885 |
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | PIK3CD, PIK3CG, PIK3R5 | GRIN2D 2340/4885GRIN3B 1705/4885GRIN1 563/4885 |
| US-20220098202-A1 | IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS | PIK3CD, PIK3R5, PIK3CA | GRIN2D 1848/4885GRIN3B 3056/4885GRIN1 1193/4885 |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | PIK3R1, PIK3R3, PIK3R2 | GRIN2D 3133/4885GRIN3B 3058/4885GRIN1 2394/4885 |
| US-20150284390-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PI4KB | GRIN2D 3104/4885GRIN3B 730/4885GRIN1 783/4885 |
| US-11725012-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | PIK3CD, PIK3R5, PIK3CA | GRIN2D 1819/4885GRIN3B 2514/4885GRIN1 868/4885 |
| US-20230009843-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | GRIN2D 3091/4885GRIN3B 2412/4885GRIN1 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.